SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study
PR Newswire —
First dose at RadNet, in partnership with Helios Clinical and The Oncology Institute of Hope and Innovation, in FAPI-GO trial for gastroesophageal cancers A second trial focused on PDAC, FAPI-PRO, launched December 2025 DULLES, Va., Dec. 29, 2025 /PRNewswire/ -- SOFIE Biosciences, an...